MedTrace Logo

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

NCT01769885 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-08-15

No results posted yet for this study

Summary

This clinical trial studies tivozanib before surgery in treating patients with localized kidney cancer. Tivozanib may stop the growth of tumor cells by blocking some of the growth factors needed for cell growth.

Conditions

  • Stage II Renal Cell Cancer
  • Stage III Renal Cell Cancer

Interventions

DRUG

tivozanib

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo nephrectomy

Sponsors & Collaborators

  • AVEO Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Saby George · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-14
Primary Completion
2013-06-14
Completion
2013-12-02

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01769885 on ClinicalTrials.gov